More likely in my mind that BP would buy Vyera out of the HIV licensing deal. This would greatly simplify the issues with off-label usage, sales attribution, etc. Particularly if NASH were also involved with a given deal, due to the heavy overlap in the HIV/NASH patient populations.

It's just a thought though. I'd be perfectly happy to have Vyera sell a whole lot of leronlimab for us.